 Study TMC114-C214 is a randomized patients are assigned to different treatment groups based on chance, controlled, open-label trial to compare the efficacy effectiveness, safety and tolerability of TMC114 boosted with low dose ritonavir RTV versus Kaletra LPVRTV in treatment-experienced HIV-1 infected patients. This research study will look at the safety of TMC114 and effectiveness in reducing the amount of HIVviral load in the blood. People included in this study will have received either Non-Nucleoside Reverse Transcriptase Inhibitors NNRTIs or Protease Inhibitors PIs or both. The duration of the study will be approximately 106 weeks, which includes a 4 to 6 week screening period, 96-week treatment period, and 4-week follow-up period. TMC114 300mg are orange tablets where 2 tablets are taken by mouth twice a day with 1 tablet of Ritonavir. Kaletra LPVRTV is either a tablet or capsule taken twice a day. The oral capsule contains 133.3 mg LPV, 33.3 mg RTV and the film-coated tablet is available for oral administration in a strength of 200 mg of lopinavir and 50 mg of ritonavir. Dosing for all medication will occur for 96 weeks and you will be randomly assigned to either TMC114 or Kaletra. 